«Opdivo has become a foundational treatment that is transforming cancer care across multiple tumor types,» chief executive Giovanni Caforio said in a statement. (fortune.com)
Emerging date has shown that IDO1 is induced during tumor development and / or after immune checkpoint treatment in multiple tumor types, helping malignant cells escape eradication by the immune system. (iteostherapeutics.com)